Table 2.
Drug-use characterization
| n (%) | |
|---|---|
| Chemsex drugs | |
| Cocaine (n = 172) | 96 (56%) |
| Ketamine (n = 172) | 74 (43%) |
| GHB/GBL (n = 172) | 132 (77%) |
| Methamphetamine (n = 172) | 136 (79%) |
| Mephedrone (n = 172) | 85 (49%) |
| Speed (n = 172) | 60 (35%) |
| Ecstasy (n = 172) | 76 (44%) |
| MDMA (n = 172) | 62 (36%) |
| Alkyl nitrites (poppers) (n = 172) | 122 (71%) |
| Erectile dysfunction agents (n = 172) | 143 (83%) |
| Cannabis (n = 172) | 51 (30%) |
| Number of drugs used (before or during chemsex) | |
| 1 drug (n = 167) | 16 (9%) |
| 2 drugs (n = 167) | 65 (38%) |
| Polydrug usea (n = 167) | 88 (52%) |
| Route of drug administration | |
| Oral (n = 170) | 128 (75%) |
| Inhaled (n = 171) | 135 (79%) |
| Sniffed (n = 172) | 113 (66%) |
| Sublingual (n = 171) | 18 (11%) |
| Rectal (n = 172) | 29 (17%) |
| Intravenous (slamming) (n = 170) | 26 (15%) |
| Frequency of use | |
| Every day (n = 167) | 11 (7%) |
| Every week (n = 169) | 76 (45%) |
| Every month (n = 168) | 65 (39%) |
| < 1 time per month (n = 165) | 29 (18%) |
Ecstasy includes “designer drugs”, MDMA 3,4-methylenedioxymethamphetamine, GHB γ-hydroxybutyric acid, GBL γ-butyrolactone
Erectile dysfunction agents include sildenafil, tadalafil, vardenafil
aActive use of three or more drugs before or during chemsex